phosphorylcholine has been researched along with Respiratory Distress Syndrome in 19 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
Respiratory Distress Syndrome: A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with acute respiratory distress syndrome (ARDS) have a deficiency of surfactant." | 2.68 | Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group. ( Anzueto, A; Baughman, RP; Guntupalli, KK; Lemaire, F; Long, W; Pattishall, EN; Raventós, AA; Weg, JG; Wiedemann, HP; Zaccardelli, DS, 1996) |
| " This is because of the severity of the injury at the time of treatment and because of the variable surfactant preparations, dosing regimes, and delivery methods used in the different trials." | 2.42 | Role of exogenous surfactant in acute lung injury. ( Brackenbury, A; Lewis, JF, 2003) |
| "During the adult respiratory distress syndrome the normally surfactant-coated alveolus becomes flooded with plasma proteins, altering the milieu of alveolar cells such as alveolar macrophages." | 1.29 | Immunosuppressive properties of surfactant and plasma on alveolar macrophages. ( Allen, JN; Marsh, CB; Moore, SA; Pope-Harman, AL; Wewers, MD, 1995) |
| "A 50-year-old man with adult respiratory distress syndrome (ARDS) was successfully treated with synthetic surfactant." | 1.29 | Successful treatment of ARDS with two doses of synthetic surfactant. ( Andersson, S; Hallman, M; Heikinheimo, M; Hynynen, M; Kukkonen, S; Rautiainen, P, 1994) |
| "Evidence for surfactant dysfunction in acute respiratory distress syndrome (ARDS) suggests a role for exogenous surfactant which contains apoprotein for resistance to protein inhibition." | 1.29 | Exogenous surfactants in a piglet model of acute respiratory distress syndrome. ( Balaraman, V; Britton, B; Easa, D; Finn, KC; Sood, SL; Uyehara, CF, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.26) | 18.7374 |
| 1990's | 14 (73.68) | 18.2507 |
| 2000's | 4 (21.05) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lewis, JF | 1 |
| Brackenbury, A | 1 |
| Ballard, PL | 1 |
| Merrill, JD | 1 |
| Godinez, RI | 1 |
| Godinez, MH | 1 |
| Truog, WE | 1 |
| Ballard, RA | 1 |
| Moen, MD | 1 |
| Perry, CM | 1 |
| Wellington, K | 1 |
| Häfner, D | 2 |
| Beume, R | 1 |
| Kilian, U | 1 |
| Krasznai, G | 1 |
| Lachmann, B | 1 |
| Perez-Benavides, F | 1 |
| Riff, E | 1 |
| Franks, C | 1 |
| Doig, C | 1 |
| Allen, JN | 1 |
| Moore, SA | 1 |
| Pope-Harman, AL | 1 |
| Marsh, CB | 1 |
| Wewers, MD | 1 |
| Weg, JG | 2 |
| Balk, RA | 1 |
| Tharratt, RS | 1 |
| Jenkinson, SG | 1 |
| Shah, JB | 1 |
| Zaccardelli, D | 1 |
| Horton, J | 1 |
| Pattishall, EN | 2 |
| Heikinheimo, M | 1 |
| Hynynen, M | 1 |
| Rautiainen, P | 1 |
| Andersson, S | 1 |
| Hallman, M | 1 |
| Kukkonen, S | 1 |
| Sood, SL | 3 |
| Balaraman, V | 3 |
| Finn, KC | 2 |
| Britton, B | 1 |
| Uyehara, CF | 2 |
| Easa, D | 3 |
| Anzueto, A | 1 |
| Baughman, RP | 1 |
| Guntupalli, KK | 1 |
| Wiedemann, HP | 1 |
| Raventós, AA | 1 |
| Lemaire, F | 1 |
| Long, W | 1 |
| Zaccardelli, DS | 1 |
| Matthay, MA | 1 |
| Wilkerson, SY | 1 |
| Mundie, TG | 1 |
| Meister, J | 1 |
| Ku, TL | 1 |
| Tam, E | 1 |
| Killeen, J | 1 |
| Egan, E | 1 |
| Gadek, JE | 1 |
| Imperatore, F | 1 |
| Postiglione, M | 1 |
| Diurno, F | 1 |
| Cirillo, F | 1 |
| Liguori, G | 1 |
| Pica, M | 1 |
| Germann, PG | 1 |
| Banerjee, R | 1 |
| Bellare, JR | 1 |
| Li, JJ | 1 |
| Sanders, RL | 1 |
| McAdam, KP | 1 |
| Hales, CA | 1 |
| Thompson, BT | 1 |
| Gelfand, JA | 1 |
| Burke, JF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000548] | Phase 3 | 0 participants | Interventional | 2000-03-31 | Completed | ||
| A Clinical Trial of Nebulized Surfactant for the Treatment of Moderate to Severe COVID-19[NCT04362059] | 20 participants (Actual) | Interventional | 2020-06-18 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for phosphorylcholine and Respiratory Distress Syndrome
| Article | Year |
|---|---|
Role of exogenous surfactant in acute lung injury.
Topics: Clinical Trials as Topic; Drug Combinations; Fatty Alcohols; Humans; Lung; Phosphorylcholine; Polyet | 2003 |
Lucinactant: in neonatal respiratory distress syndrome.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Animals; Animals, Newborn; Biological Products; Drug Combination | 2005 |
Consensus on surfactant and inhaled nitric oxide for ARDS.
Topics: Administration, Inhalation; Adult; Aerosols; Animals; Biological Products; Cattle; Drug Combinations | 1996 |
3 trials available for phosphorylcholine and Respiratory Distress Syndrome
| Article | Year |
|---|---|
Adult respiratory distress syndrome and artificial surfactant replacement in the pediatric patient.
Topics: Child; Child, Preschool; Drug Combinations; Fatty Alcohols; Female; Humans; Infant; Male; Near Drown | 1995 |
Safety and potential efficacy of an aerosolized surfactant in human sepsis-induced adult respiratory distress syndrome.
Topics: Adult; Aerosols; Aged; APACHE; Double-Blind Method; Drug Administration Schedule; Drug Combinations; | 1994 |
Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group.
Topics: Administration, Inhalation; Aerosols; Double-Blind Method; Drug Combinations; Fatty Alcohols; Female | 1996 |
13 other studies available for phosphorylcholine and Respiratory Distress Syndrome
| Article | Year |
|---|---|
Surfactant protein profile of pulmonary surfactant in premature infants.
Topics: Blotting, Western; Drug Combinations; Fatty Alcohols; Female; Humans; Infant; Infant, Newborn; Infan | 2003 |
Dose-response comparisons of five lung surfactant factor (LSF) preparations in an animal model of adult respiratory distress syndrome (ARDS).
Topics: Animals; Biological Products; Blood Gas Analysis; Cattle; Disease Models, Animal; Dose-Response Rela | 1995 |
Aerosolized surfactant in sepsis-induced adult respiratory distress syndrome.
Topics: Drug Combinations; Fatty Alcohols; Humans; Phosphorylcholine; Polyethylene Glycols; Pulmonary Surfac | 1995 |
Immunosuppressive properties of surfactant and plasma on alveolar macrophages.
Topics: Biological Products; Bronchoalveolar Lavage Fluid; Drug Combinations; Enzyme-Linked Immunosorbent As | 1995 |
Successful treatment of ARDS with two doses of synthetic surfactant.
Topics: Drug Combinations; Fatty Alcohols; Humans; Male; Middle Aged; Phosphorylcholine; Polyethylene Glycol | 1994 |
Exogenous surfactants in a piglet model of acute respiratory distress syndrome.
Topics: Animals; Animals, Newborn; Biological Products; Bronchoalveolar Lavage Fluid; Drug Combinations; Fat | 1996 |
The acute respiratory distress syndrome.
Topics: Aerosols; Drug Combinations; Fatty Alcohols; Humans; Phosphorylcholine; Polyethylene Glycols; Pulmon | 1996 |
Exogenous surfactant decreases oxygenation in Escherichia coli endotoxin-treated neonatal piglets.
Topics: Animals; Animals, Newborn; Biological Products; Bronchoalveolar Lavage Fluid; Disease Models, Animal | 1996 |
Lavage administration of dilute surfactants after acute lung injury in neonatal piglets.
Topics: Animals; Animals, Newborn; Bronchoalveolar Lavage; Disease Models, Animal; Drug Combinations; Fatty | 1998 |
The instillated surfactant in the treatment of sepsis-induced ARDS: case report.
Topics: Bronchi; Drug Combinations; Fatty Alcohols; Humans; Phosphorylcholine; Polyethylene Glycols; Pulmona | 1999 |
Dexamethasone enhances the activity of rSP-C surfactant but not of exosurf in a rat model of the acute lung injury.
Topics: Animals; Cell Movement; Dexamethasone; Drug Combinations; Drug Synergism; Fatty Alcohols; Lung; Male | 1999 |
Scoring of surface parameters of physiological relevance to surfactant therapy in respiratory distress syndrome.
Topics: Drug Combinations; Fatty Alcohols; Phospholipids; Phosphorylcholine; Polyethylene Glycols; Pulmonary | 2001 |
Impact of C-reactive protein (CRP) on surfactant function.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Bronchoalveolar Lavage Fluid; C-Reactive Protein; Choline; Enzym | 1989 |